Relatlimab

Relatlimab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Lymphocyte activation gene-3 (LAG-3)
Clinical data
Other names	BMS-986016, relatlimab-rmbw
License data	US DailyMed: Relatlimab;
Routes of; administration	Intravenous
Drug class	Antineoplastic
ATC code	None;
Legal status
Legal status	US: ℞-only only in combination with nivolumab[1];
Identifiers
CAS Number	1673516-98-7;
DrugBank	DB14851;
UNII	AF75XOF6W3;
KEGG	D11350;
Chemical and physical data
Formula	C6472H9922N1710O2024S38
Molar mass	145288.79 g·mol−1

Relatlimab is a monoclonal antibody designed for the treatment of melanoma.[2][3] It is used in combination with nivolumab to treat melanoma.[1][4]

Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor.[1][4] It is under development by Bristol-Myers Squibb.[1][4] It is made using Chinese hamster ovary cells.[1]

History

As of 2018, relatlimab is undergoing Phase II/III trials.[5]

The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.[1][4]

Names

Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).[6][7][8]

References

"Opdualag- nivolumab and relatlimab-rmbw injection". DailyMed. 18 March 2022. Retrieved 22 March 2022.
Cavagnaro JA, Cosenza ME, eds. (2021). Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals. Boca Raton, Florida: CRC Press. ISBN 978-1-00-047185-4.
Robert C (December 2021). "LAG-3 and PD-1 blockade raises the bar for melanoma". Nature Cancer. 2 (12): 1251–3. doi:10.1038/s43018-021-00276-8. PMID 35121906. S2CID 245407697.
"U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma" (Press release). Bristol Myers Squibb. 18 March 2022. Retrieved 19 March 2022 – via Business Wire.
Clinical trial number NCT03704077 for "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" at ClinicalTrials.gov
"Relatlimab". American Medical Association. Retrieved 22 March 2022.
Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab, American Medical Association.
World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.

External links

"Relatlimab". Drug Information Portal. U.S. National Library of Medicine.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Opdualag_FDA_label-1] "Opdualag- nivolumab and relatlimab-rmbw injection". DailyMed. 18 March 2022. Retrieved 22 March 2022.

[2] Cavagnaro JA, Cosenza ME, eds. (2021). Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals. Boca Raton, Florida: CRC Press. ISBN 978-1-00-047185-4.

[3] Robert C (December 2021). "LAG-3 and PD-1 blockade raises the bar for melanoma". Nature Cancer. 2 (12): 1251–3. doi:10.1038/s43018-021-00276-8. PMID 35121906. S2CID 245407697.

[Opdualag_PR-4] "U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma" (Press release). Bristol Myers Squibb. 18 March 2022. Retrieved 19 March 2022 – via Business Wire.

[GI_study-5] Clinical trial number NCT03704077 for "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" at ClinicalTrials.gov

[6] "Relatlimab". American Medical Association. Retrieved 22 March 2022.

[7] Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab, American Medical Association.

[8] World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.